(MedPage Today) — Adding the menin inhibitor revumenib (Revuforj) to azacitidine and venetoclax (Venclexta) seemed to benefit older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged acute myeloid leukemia (AML), according to results…
Source link : https://www.medpagetoday.com/meetingcoverage/eha/116071
Author :
Publish date : 2025-06-13 18:01:00
Copyright for syndicated content belongs to the linked Source.
